Prospective Observational Epidemiologic Study of Maraviroc's Safety

• Status: Completed
• Trial end date: 2019-02-14
• Target enrollment: 0
• Participant gender: All

Summary

The study will assess if use of maraviroc along with an optimized background regimen of antiretroviral drugs in usual clinical practice is as safe as using only an optimized regimen of antiretroviral drugs.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ViiV Healthcare
• Collaborator: Pfizer
• Treatments: Anti-Retroviral Agents; Maraviroc

Criteria

Inclusion Criteria:

• Treatment experienced, HIV-1 infected patients

• 18 years or older

• Receive an approved assay for determination of HIV-1 tropism

Exclusion Criteria:

• Pregnant or lactating

• Using CCR5 inhibitor other than maraviroc